Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CET056
- Development stage
- Preclinical
- Lead developer
- Oregon Health & Science University
01
Overview
CET056: sourced facts only. name: "We recently described a novel compound, CET056, that inhibits cancer progression via YB-1 inhibition." [DOI:10.1158/1538-7445.am2024-5926]; target: "We recently described a novel compound, CET056, that inhibits cancer progression via YB-1 inhibition." [DOI:10.1158/1538-7445.am2024-5926]; developer: "1Knight Cancer Institute, Oregon Health & Science University, Portland, OR;" [DOI:10.1158/1538-7445.am2024-5926]; stage: "In vivo efficacy studies, which employed a syngeneic subcutaneous tumor model, revealed that CET056 effectively inhibited tumor progression and enhanced overall survival in contrast to vehicle treated control mice." [DOI:10.1158/1538-7445.am2024-5926]
02
Targets
YBX1 (Y-box-binding protein 1)
Beyond the preview
Go deeper on CET056.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CET056.